{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:04:40Z","timestamp":1790795080304,"version":"4.1.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","jcehepatology.com","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical and Experimental Hepatology"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.jceh.2024.101398","type":"journal-article","created":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T17:44:22Z","timestamp":1710783862000},"page":"101398","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["A Prospective Randomised Comparative Four-arm Intervention Study of Efficacy and Safety of Saroglitazar and Vitamin E in Patients With Non-alcoholic Fatty Liver Disease (NAFLD)\/Non-alcoholic Steatohepatitis (NASH)-SVIN TRIAL"],"prefix":"10.1016","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0765-6566","authenticated-orcid":false,"given":"Bilal A.","family":"Mir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brij","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishal","family":"Bodh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish","family":"Chauhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tahir","family":"Majeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inaamul","family":"Haq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neetu","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dikshant","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jceh.2024.101398_bib1","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.2337\/diabetes.50.8.1844","article-title":"Nonalcoholic fatty liver disease: a feature of the metabolic syndrome","volume":"50","author":"Marchesini","year":"2001","journal-title":"Diabetes"},{"key":"10.1016\/j.jceh.2024.101398_bib2","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease: metanalytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2024.101398_bib3","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1053\/gast.2001.23256","article-title":"Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities","volume":"120","author":"Sanyal","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jceh.2024.101398_bib4","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jceh.2012.10.009","article-title":"Patients with nonalcoholic fatty liver disease (NAFLD) have higher oxidative stress in comparison to chronic viral hepatitis","volume":"3","author":"Kumar","year":"2013","journal-title":"J\u00a0Clin Exp Hepatol"},{"key":"10.1016\/j.jceh.2024.101398_bib5","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","article-title":"Weight loss through lifestyle modification significantly reduces features of nonalcoholic steato-hepatitis","volume":"149","author":"Vilar-Gomez","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jceh.2024.101398_bib6","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1111\/liv.12483","article-title":"Readiness for behaviour change in nonalcoholic fatty liver disease: implications for multidisciplinary care models","volume":"35","author":"Stewart","year":"2015","journal-title":"Liver Int"},{"key":"10.1016\/j.jceh.2024.101398_bib7","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis","volume":"362","author":"Sanyal","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jceh.2024.101398_bib8","doi-asserted-by":"crossref","DOI":"10.1177\/1756284820974917","article-title":"The efficacy of vitamin E in reducing non-alcoholic fatty liver disease: a systematic review, meta-analysis, and meta-regression","volume":"13","author":"Abdel-Maboud","year":"2020","journal-title":"Therapeutic Advances in Gastroenterology"},{"key":"10.1016\/j.jceh.2024.101398_bib9","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.bbagrm.2016.03.002","article-title":"Nuclear receptors and nonalcoholic fatty liver disease","volume":"1859","author":"Cave","year":"2016","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.jceh.2024.101398_bib10","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.136","article-title":"Saroglitazar, a novel PPARalpha\/gamma agonist with predominant PPARalpha activity, shows lipid-lowering and insulin-sensitizing effects in preclinical models","volume":"3","author":"Jain","year":"2015","journal-title":"Pharmacol Res Perspect"},{"key":"10.1016\/j.jceh.2024.101398_bib11","article-title":"A\u00a0phase 2, prospective, multicentre, double-blind, randomized study of Saroglitazar magnesium 1 mg, 2 mg or 4 mg versus placebo in patients with nonalcoholic fatty liver disease and\/or nonalcoholic steatohepatitis (EVIDENCES IV)","volume":"70","author":"Gawrieh","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2024.101398_bib12","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1002\/hep.29639","article-title":"Optimal threshold of controlled attenuation parameter with MRI-PDFF as the gold standard for the detection of hepatic steatosis","volume":"67","author":"Caussy","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2024.101398_bib13","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.dld.2007.10.019","article-title":"Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with nonalcoholic fatty liver disease (NAFLD)","volume":"40","author":"Yoneda","year":"2008","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.jceh.2024.101398_bib14","doi-asserted-by":"crossref","first-page":"128","DOI":"10.3350\/cmh.2019.0001n","article-title":"Application of transient elastography in nonalcoholic fatty liver disease","volume":"26","author":"Zhang","year":"2020","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.jceh.2024.101398_bib15","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2024.101398_bib16","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.cct.2008.09.003","article-title":"Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design","volume":"30","author":"Chalasani","year":"2009","journal-title":"Contemp Clin Trials"},{"key":"10.1016\/j.jceh.2024.101398_bib17","series-title":"The Asian Pacific perspective. Redefining Obesity and its Treatment","year":"2000"},{"key":"10.1016\/j.jceh.2024.101398_bib18","first-page":"46","article-title":"Nationwide registry on nonalcoholic fatty liver disease (NAFLD)-ICON-D (Indian Consortium on NAFLD) study","volume":"34","author":"Duseja","year":"2019","journal-title":"J\u00a0Gastroeterol Hepatol"},{"key":"10.1016\/j.jceh.2024.101398_bib19","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jceh.2022.11.014","article-title":"Indian National association for study of the liver (INASL) guidance paper on nomenclature, diagnosis and treatment of nonalcoholic fatty liver disease (NAFLD)","volume":"13","author":"Duseja","year":"2023","journal-title":"J\u00a0Clin Exp Hepatol"},{"key":"10.1016\/j.jceh.2024.101398_bib20","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.3748\/wjg.v12.i21.3400","article-title":"Non-alcoholic fatty liver disease may not be a severe disease at presentation among Asian Indians","volume":"12","author":"Madan","year":"2006","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jceh.2024.101398_bib21","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S1665-2681(19)31922-2","article-title":"Prevalence of non-alcoholic fatty liver disease: population based study","volume":"6","author":"Amarapurkar","year":"2007","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.jceh.2024.101398_bib22","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1002\/hep.23838","article-title":"Nonalcoholic fatty liver in a developing country is responsible for significant liver disease","volume":"52","author":"Duseja","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2024.101398_bib23","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1089\/met.2021.0104","article-title":"Clinicopathological profile and outcome of a large cohort of patients with nonalcoholic fatty liver disease from south Asia: interim results of the Indian Consortium on nonalcoholic fatty liver disease","volume":"20","author":"Duseja","year":"2022","journal-title":"Metab Syndr Relat Disord"},{"key":"10.1016\/j.jceh.2024.101398_bib24","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1089\/met.2021.0104","article-title":"Clinicopathological profile and outcome of a large cohort of patients with nonalcoholic fatty liver disease from south Asia: interim results of the Indian Consortium on nonalcoholic fatty liver disease","volume":"20","author":"Duseja","year":"2022","journal-title":"Metab Syndr Relat Disord"},{"key":"10.1016\/j.jceh.2024.101398_bib25","doi-asserted-by":"crossref","first-page":"665","DOI":"10.4103\/2230-8210.113758","article-title":"Clinicopathological characteristics and metabolic profiles of non-alcoholic fatty liver disease in Indian patients with normal body mass index: do they differ from obese or overweight non-alcoholic fatty liver disease?","volume":"17","author":"Kumar","year":"2013","journal-title":"Indian J Endocrinol Metab"},{"key":"10.1016\/j.jceh.2024.101398_bib26","doi-asserted-by":"crossref","first-page":"665","DOI":"10.4103\/2230-8210.113758","article-title":"Clinicopathological characteristics and metabolic profiles of non-alcoholic fatty liver disease in Indian patients with normal body mass index: do they differ from obese or overweight non-alcoholic fatty liver disease?","volume":"17","author":"Kumar","year":"2013","journal-title":"Indian J Endocrinol Metab"},{"key":"10.1016\/j.jceh.2024.101398_bib27","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1111\/j.1572-0241.2003.08699.x","article-title":"Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis","volume":"98","author":"Harrison","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jceh.2024.101398_bib28","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/8742075","article-title":"Evaluation of the effect\u00a0derived from silybin with vitamin D and vitamin E administration on clinical, metabolic, endothelial dysfunction, oxidative stress parameters, and serological worsening markers in nonalcoholic fatty liver disease patients","volume":"2019","author":"Federico","year":"2019","journal-title":"Oxid Med Cell Longev"},{"key":"10.1016\/j.jceh.2024.101398_bib29","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-78342-x","article-title":"Saroglitazar in patients with non-alcoholic fatty liver disease and diabetic dyslipidemia: a prospective, observational, real world study","volume":"10","author":"Goyal","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.jceh.2024.101398_bib30","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s12933-019-0884-3","article-title":"New dual peroxisome proliferator activated receptoragonist- Saroglitazar in diabetic dyslipidemia and non alcoholic fatty liver disease: integrated analysis of the real world evidence","volume":"18","author":"Kaul","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jceh.2024.101398_bib31","article-title":"Role of saroglitazar in nondiabetic and nonalcoholic fatty liver disease: a retrospective observational study","volume":"15","author":"Jaiswal","year":"2021","journal-title":"J\u00a0Clin Digest Res"},{"key":"10.1016\/j.jceh.2024.101398_bib32","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/4287075","article-title":"Clinical case series of decrease in shear wave elastography values in ten diabetic dyslipidaemia patients having NAFLD with Saroglitazar 4 mg: an Indian experience","author":"Roy","year":"2020","journal-title":"Case Rep Med"},{"key":"10.1016\/j.jceh.2024.101398_bib33","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jceh.2021.03.012","article-title":"Safety and efficacy of saroglitazar in nonalcoholic fatty liver patients with diabetic dyslipidemia-A prospective, interventional, pilot study","volume":"12","author":"Rajesh","year":"2022","journal-title":"J\u00a0Clin Exp Hepatol"}],"container-title":["Journal of Clinical and Experimental Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0973688324000550?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0973688324000550?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T22:44:12Z","timestamp":1725576252000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0973688324000550"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S0973688324000550"],"URL":"https:\/\/doi.org\/10.1016\/j.jceh.2024.101398","relation":{},"ISSN":["0973-6883"],"issn-type":[{"value":"0973-6883","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Prospective Randomised Comparative Four-arm Intervention Study of Efficacy and Safety of Saroglitazar and Vitamin E in Patients With Non-alcoholic Fatty Liver Disease (NAFLD)\/Non-alcoholic Steatohepatitis (NASH)-SVIN TRIAL","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical and Experimental Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jceh.2024.101398","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Indian National Association for Study of the Liver. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101398"}}